Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

Clinical trial NCT07416890 · RECRUITING

Trial details

NCT number

NCT07416890

Sponsor

Zhejiang Cancer Hospital

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2026-02-10

Primary completion

2028-08-05

Enrollment

24

View on ClinicalTrials.gov